PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27034161-3	2016	More recently, RET over-expression has emerged as a new player in ER-positive (ER+) BC, and as a potential target to enhance sensitivity and avoid resistance to tamoxifen therapy.Therefore, targeting the RET pathway may lead to new therapies in ER+ BC.	Tamoxifen	161-170	ret proto-oncogene	Homo sapiens	15-18	
27034161-3	2016	More recently, RET over-expression has emerged as a new player in ER-positive (ER+) BC, and as a potential target to enhance sensitivity and avoid resistance to tamoxifen therapy.Therefore, targeting the RET pathway may lead to new therapies in ER+ BC.	Tamoxifen	161-170	ret proto-oncogene	Homo sapiens	204-207	
24526731-10	2014	CONCLUSIONS: Vandetanib potentiated the antigrowth effects of tamoxifen in breast cancer, which was mediated through RET activation.	Tamoxifen	62-71	ret proto-oncogene	Homo sapiens	117-120	
25409876-9	2014	In MCF7 cells, SPP86 inhibited RET- induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling and estrogen receptoralpha (ERalpha) phosphorylation, and inhibited proliferation to a similar degree as tamoxifen.	Tamoxifen	211-220	ret proto-oncogene	Homo sapiens	31-34	
24045439-11	2014	Parallel experiments using treatment with tamoxifen and sunitinib confirmed the increased effectiveness of dual inhibition of the ER and RET pathways in regulating cell growth.	Tamoxifen	42-51	ret proto-oncogene	Homo sapiens	137-140	
21737465-1	2011	RET, a gene causatively mutated in Hirschsprung disease and cancer, has recently been implicated in breast cancer estrogen (E2) independence and tamoxifen resistance.	Tamoxifen	145-154	ret proto-oncogene	Homo sapiens	0-3	
24563328-3	2014	The expression analysis of selected genes involved in tamoxifen/estrogen and receptor tyrosine kinase signaling pathways can help to further decipher mechanisms of recurrence in ER+ tumors and contribute to the development of prognostic and possibly predictive biomarkers.	Tamoxifen	54-63	ret proto-oncogene	Homo sapiens	77-101	
20531297-0	2010	Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.	Tamoxifen	77-86	ret proto-oncogene	Homo sapiens	39-42	
20531297-5	2010	In tamoxifen response experiments, RET downregulation resulted in 6.2-fold increase in sensitivity of MCF7 cells to antiproliferative effects of tamoxifen, whereas GDNF stimulation had a protective effect against the drug.	Tamoxifen	3-12	ret proto-oncogene	Homo sapiens	35-38	
20531297-5	2010	In tamoxifen response experiments, RET downregulation resulted in 6.2-fold increase in sensitivity of MCF7 cells to antiproliferative effects of tamoxifen, whereas GDNF stimulation had a protective effect against the drug.	Tamoxifen	145-154	ret proto-oncogene	Homo sapiens	35-38	
20531297-6	2010	In tamoxifen-resistant (TAM(R)-1) MCF7 cells, targeting RET restored tamoxifen sensitivity.	Tamoxifen	3-12	ret proto-oncogene	Homo sapiens	56-59	
20531297-6	2010	In tamoxifen-resistant (TAM(R)-1) MCF7 cells, targeting RET restored tamoxifen sensitivity.	Tamoxifen	69-78	ret proto-oncogene	Homo sapiens	56-59	
20531297-7	2010	Finally, examination of two independent tissue microarrays of primary human breast cancers revealed that expression of RET protein was significantly associated with ERalpha-positive tumors and that in primary tumors from patients who subsequently developed invasive recurrence after adjuvant tamoxifen treatment, there was a twofold increase in the number of RET-positive tumors.	Tamoxifen	292-301	ret proto-oncogene	Homo sapiens	119-122	
20531297-7	2010	Finally, examination of two independent tissue microarrays of primary human breast cancers revealed that expression of RET protein was significantly associated with ERalpha-positive tumors and that in primary tumors from patients who subsequently developed invasive recurrence after adjuvant tamoxifen treatment, there was a twofold increase in the number of RET-positive tumors.	Tamoxifen	292-301	ret proto-oncogene	Homo sapiens	359-362	
20531297-8	2010	Together these findings identify RET as a potentially important therapeutic target in ERalpha-positive breast cancers and in particular in tamoxifen-resistant tumors.	Tamoxifen	139-148	ret proto-oncogene	Homo sapiens	33-36	
20689759-0	2010	Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.	Tamoxifen	62-71	ret proto-oncogene	Homo sapiens	4-28	
20689759-9	2010	In summary, these results illustrate a novel connection between the Ron receptor tyrosine kinase and an important mechanism of tamoxifen resistance in breast cancer.	Tamoxifen	127-136	ret proto-oncogene	Homo sapiens	72-96